Date published: 2026-3-9

1-800-457-3801

SCBT Portrait Logo
Seach Input

BLNK Inhibitors

BLNK inhibitors belong to a distinct chemical class that has garnered significant attention within the realm of cellular signaling and molecular pathways. These inhibitors target the signaling protein known as B cell linker protein (BLNK), which plays a crucial role in mediating signal transduction from the B cell receptor (BCR) to downstream effector molecules. BLNK, also referred to as SLP-65 (SH2 domain-containing leukocyte protein of 65 kDa), acts as a central hub for assembling key signaling molecules in the BCR pathway. It contains multiple protein interaction motifs, including tyrosine phosphorylation sites and SH2 domains, that facilitate the recruitment and coordination of various downstream signaling components. BLNK is pivotal in initiating B cell activation, maturation, and differentiation processes by transmitting signals from the extracellular environment to the nucleus, resulting in cellular responses like proliferation and antibody production. The class of BLNK inhibitors is characterized by their ability to modulate BCR signaling by specifically disrupting the interactions involving BLNK. These inhibitors function by binding to critical domains within BLNK, often those responsible for protein-protein interactions, thereby obstructing the assembly of downstream signaling complexes. By interfering with these interactions, BLNK inhibitors can profoundly impact the transduction of BCR-mediated signals and subsequently alter the cellular outcomes of B cell activation. These compounds have attracted attention as valuable research tools for dissecting the intricacies of B cell signaling pathways, shedding light on the molecular events underlying immune responses. Their selective interference with BLNK-associated signaling cascades holds promise for uncovering novel insights into the fundamental processes governing B cell biology. As our understanding of BLNK's role in cellular signaling deepens, so does the significance of BLNK inhibitors in advancing our knowledge of immune system regulation and related molecular mechanisms.

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Ibrutinib

936563-96-1sc-483194
10 mg
$156.00
5
(0)

A Bruton's tyrosine kinase (BTK) inhibitor that indirectly affects BLNK-mediated signaling by disrupting the B cell receptor pathway. It was investigated for B cell malignancies and autoimmune disorders.

R788

901119-35-5sc-364597
sc-364597A
2 mg
50 mg
$405.00
$4000.00
2
(0)

A spleen tyrosine kinase (SYK) inhibitor that impacts downstream signaling events involving BLNK. It was studied for immune thrombocytopenic purpura (ITP) and other autoimmune conditions.

Acalabrutinib

1420477-60-6sc-507392
250 mg
$255.00
(0)

Another BTK inhibitor that interferes with BLNK-associated signaling pathways. It has been explored in various B cell-related disorders, including certain lymphomas.

CAL-101

870281-82-6sc-364453
10 mg
$193.00
4
(1)

A phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor that could indirectly affect BLNK-mediated PI3K signaling. It was researched for B cell malignancies like chronic lymphocytic leukemia (CLL).

Spebrutinib

1202757-89-8sc-507524
100 mg
$375.00
(0)

A BTK inhibitor that might influence BLNK signaling pathways, and was being investigated for B cell disorders and autoimmune diseases.

GS 9973

1229208-44-9sc-490337
sc-490337A
sc-490337B
sc-490337C
sc-490337D
10 mg
50 mg
100 mg
500 mg
1 g
$250.00
$878.00
$1353.00
$5500.00
$9000.00
(0)

A SYK inhibitor with potential effects on BLNK-related signaling events, studied in various hematologic malignancies.

IPI 145

1201438-56-3sc-488318
5 mg
$317.00
(0)

A dual PI3Kδ/PI3Kγ inhibitor that could impact BLNK-associated PI3K signaling. It was explored for lymphoid malignancies.

Zanubrutinib

1691249-45-2sc-507434
5 mg
$360.00
(0)

Yet another BTK inhibitor that modulates BLNK-mediated pathways. It was researched for B cell lymphomas and other conditions.

Tirabrutinib

1351636-18-4sc-507435
10 mg
$138.00
(0)

A reversible BTK inhibitor that might affect BLNK-associated signaling cascades, undergoing investigation for B cell malignancies.

TGR-1202

1532533-67-7sc-507436
25 mg
$286.00
(0)

A dual PI3Kδ/CK1ε inhibitor that could influence BLNK-related PI3K signaling pathways. It was being studied for hematologic cancers.